Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial

Darryl P. Leong,Tammy Cosman,Muhammad M. Alhussein,Nidhi Kumar Tyagi,Sarah Karampatos,Carly C. Barron,Douglas Wright,Vikas Tandon,Patrick Magloire,Philip Joseph,David Conen,P.J. Devereaux,Peter M. Ellis,Som D. Mukherjee,Sukhbinder Dhesy-Thind

JACC: CardioOncology（2019）

引用 60|浏览46

暂无评分

摘要

It may be feasible to continue trastuzumab despite mild cardiotoxicity in the setting of a cardio-oncology clinic, where ACE inhibitors and beta-blockers are administered. Approximately 10% of patients may develop moderate to severe heart failure using this approach. (Safety of Continuing Chemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to Human Epidermal Growth Factor Receptor-2 [SCHOLAR]; NCT02907021).

查看译文

关键词

breast cancer,cardiomyopathy,HER2,trastuzumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要